Outlook of the postmenopausal osteoporosis drugs market
Technavio’s market research analyst predicts the global postmenopausal osteoporosis drugs market to grow steadily at a CAGR of more than 4% over the forecast period. With the expected launch of promising pipeline molecules, the market for postmenopausal osteoporosis has a positive outlook in the coming years. The postmenopausal osteoporosis drugs market is characterized by the presence of promising late-stage molecules that are being developed by the major and upcoming players in this market. Some of the late-stage pipeline molecules that are envisaged to be launched during the forecast period are Tarsa Therapeutics’ TBRIA, romosozumab, Merck’ odanacatib (Phase III), and Radius Health’s abaloparatide (Phase III).
In this industry research report, the analysts have estimated factors such as the emergence of combination therapies to contribute to this market’s growth in the next four years. Anabolic and antiresorptive agents can significantly enhance bone density and strength as a combination therapy than as monotherapy. Clinical trials have been performed evaluating the effect of PTH1-34 or PTH1-84 in combination with antiresorptive drugs, including raloxifene, alendronate, and risedronate. Moreover, it has been observed that combining antiresorptive drugs with PTH or teriparatide has been successful in providing greater bone mineral density. For instance, Pfizer's Duavee is a combination of conjugated estrogens and bazedoxifene used in the treatment of postmenopausal osteoporosis with few side effects.
Segmentation by line of therapy and analysis of the postmenopausal osteoporosis drugs market
- First line of therapy
- Second line of therapy
During 2015, the first line of therapy segment dominated the market and accounted for more than 64% of the market share. Optimal consumption of calcium and vitamin D is recommended as the first line of therapy to prevent and treat osteoporosis. Whereas, biphosphates are considered as a baseline preventive treatment for low bone density and glucocorticoid-induced osteoporosis in postmenopausal women. The second line of therapy is given when the initial treatment fails or is not tolerated by the patient, thereby aiding in the growth prospects of this market segment over the predicted period.
Geographical segmentation and analysis of the postmenopausal osteoporosis drugs market
The Americas dominated the postmenopausal osteoporosis drugs market and accounted for nearly 46% of the market share during 2015. The US was the largest revenue contributor to the region because of the increased prevalence of the disease. Factors such as the increasing patient population and easy availability of drugs will contribute to the growth of this market in the region.
Competitive landscape and key vendors
The global postmenopausal osteoporosis drugs market is highly competitive due to the presence of several international and regional vendors. The market is open to new players and has a lot of opportunities for growth. The competitive environment is expected to increase in due to the product extensions, new products, and new applications of the products and services provided.
Key vendors in this market are –
- Eli Lilly
- Amgen
- Merck
- Novartis
Other prominent vendors analyzed in this market research report are Allergan, Amgen Astellas Biopharm K.K., Deltanoid Pharmaceuticals, Noven, Novo Nordisk, Osteologix, Pfizer, PhytoHealth Corporation, Radius Health, Tarsa Therapeutics, UCB, Uni-Bio Science Group Limited, Upsher-Smith Laboratories, Watson Pharmaceuticals, and Zosano Pharma Inc.
Key questions answered in the report include
- What will the market size and the growth rate be in 2020?
- What are the key factors driving the global postmenopausal osteoporosis drugs market?
- What are the key market trends impacting the growth of the global postmenopausal osteoporosis drugs market?
- What are the challenges to market growth?
- Who are the key vendors in the global postmenopausal osteoporosis drugs market?
- What are the market opportunities and threats faced by the vendors in the global postmenopausal osteoporosis drugs market?
- Trending factors influencing the market shares of the Americas, APAC, and EMEA.
- What are the key outcomes of the five forces analysis of global postmenopausal osteoporosis drugs market?
Technavio also offers customization on reports based on specific client requirement.
Related reports:
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
PART 05: Disease overview
- Understanding postmenopausal osteoporosis
- Epidemiology and demography
- Risk factors
- Symptoms
- Diagnosis
- Treatment
PART 06: Key buying criteria
PART 07: Pipeline scenario
- TBRIA
- Romosozumab (AMG785)
- Odanacatib (MK-0822)
- Abaloparatide SC/Abaloparatide transdermal patch
- PHN-031 (PH3)
- NB S101
- Teriparatide ZP Patch (ZP-PTH)
- Blosozumab (LY2541546)
PART 08: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 09: Market segmentation by therapeutic class
- Antiresorptive medications
- Anabolic medications
PART 10: Market segmentation by line of therapy
PART 11: Geographical segmentation
- Global postmenopausal osteoporosis drugs market by geographical segmentation 2015-2020
- Postmenopausal osteoporosis drugs market in Americas
- Postmenopausal osteoporosis drugs market in EMEA
- Postmenopausal osteoporosis drugs market in APAC
PART 12: Market drivers
- Increase in older population
- Growing prevalence of postmenopausal osteoporosis
- Expected launch of promising pipeline molecules
- High unmet medical needs
PART 13: Impact of drivers
PART 14: Market challenges
- Multiple patent expiries
- Low diagnosis rate
- Nonadherence to treatment regimen
- Drug reimbursement issues
PART 15: Impact of drivers and challenges
PART 16: Market trends
- Awareness programs and initiatives
- Emergence of novel agents
- Emergence of combination therapies
PART 17: Vendor landscape
- Competitive scenario
- Market analysis 2015
- Eli Lilly
- Amgen
- Merck
- Novartis
- Other prominent vendors
PART 18: Appendix
PART 19: Explore Technavio